The global adult malignant glioma therapeutics market size was estimated to be USD 2.28 billion in 2023 and is expected to reach at USD 6.09 billion by 2034 with a CAGR of 9.35% during the forecast period 2024-2034. The increasing prevalence of brain cancer & malignant gliomas, heightened government funding to accelerate the development of therapeutics for malignant gliomas, growing collaborations for the innovation of therapeutic approaches, a rise in the elderly population, a surging demand for oral medications, an uptick in the introduction of innovative therapeutics, and rising approval of novel therapeutics for adult malignant gliomas are the several key factors contribute to the growth of the market.
Rising approval of novel therapeutics for adult malignant gliomas is predicted to boost the market growth during the forecast period. Malignant glioma encompasses a diverse group of tumors affecting the brain and spinal cord, originating from glial cells that support nerve cells in the brain. Tumors can develop from three types of glial cells, known as gliomas. Classification of gliomas is based on the tumor's genetic characteristics and the specific glial cell involved, aiding in predicting the tumor's behavior over time. Symptoms of gliomas include headaches, nausea or vomiting, confusion, decreased brain function, memory loss, seizures, vision problems, among others. With an increasing number of patients, market leaders are actively engaged in the development of innovative therapeutics. For instance, in April 2022, CNS Pharmaceuticals, Inc., has obtained approval from the National Agency for the Safety of Medicine and Health Products (ANSM) Competent Authority and the People Protection Ethics Committee (EC) SUD-EST III (CPP Sud-Est III) in France for the Company's potentially pivotal study of Berubicin in treating recurrent glioblastoma multiforme (GBM).
By type, glioblastoma multiforme (GBM) was the highest revenue-grossing segment in the global adult malignant glioma therapeutics market in 2023 owing to the increased approvals of novel treatments by industry participants and a rise in the number of clinical trial developments. For instance, in December 2022, Moleculin Biotech, Inc., reported that the U.S. Food and Drug Administration ("FDA") has awarded Fast Track designation to WP1122 for addressing Glioblastoma Multiforme ("GBM"). Additionally, anaplastic astrocytoma is predicted to grow at the fastest CAGR during the forecast period owing to the increasing number of surgeries is being performed to treat anaplastic astrocytoma with chemotherapy and radiation therapy and growing launch of novel therapies.
By therapy, targeted drug therapy was the highest revenue-grossing segment in the global adult malignant glioma therapeutics market in 2023 owing to the insufficient outcome of treatments such as surgery, radiation, and chemotherapy, the growing number of researched on the unregulated molecular pathways of gliomas, and the increasing emphasis on the development of new treatments. For instance, in November 2023, Novocure has disclosed that at the 2023 Society for Neuro-Oncology (SNO) Annual Meeting in Vancouver, Canada, there will be presentations on Tumor Treating Fields (TTFields) therapy, encompassing fresh data from the phase 2 2-THE-TOP trial and real-world evidence from patients diagnosed with glioblastoma (GBM) and other central nervous system tumors (CNS). Additionally, radiation therapy is predicted to grow at the fastest CAGR during the forecast period owing to the Increasing the use of external beam radiation after surgery, which is advised as the usual course of treatment for individuals with malignant gliomas.
By end-user, hospitals was the highest revenue-grossing segment in the global adult malignant glioma therapeutics market in 2023 owing to the growing number of patients suffering from brain cancer and increasing regulatory approvals of innovative therapeutic options. For instance, in August 2023, according to a statement from Lisata Therapeutics, Inc., the FDA has designated LSTA1 (CEND-1) as an orphan medication for use as a possible treatment option in patients with malignant glioma. Additionally, cancer and radiation therapy centers is predicted to grow at the fastest CAGR during the forecast period owing to the rising prevalence of cancer, increasing number of clinical trial procedures, and surge in development of novel therapies.
North America region is anticipated for the highest revenue share during the forecast period owing to the increasing incidence of adult malignant glioma, increased emphasis on the development of novel treatments, and an increase in the number of clinical trial methods. For instance, in March 2022, A Phase 0/Ib clinical study of AstraZeneca's AZD1390 has been initiated in patients with recurrent grade IV gliomas at the Barrow Neurological Institute in the US by the Ivy Brain Tumor Center. Additionally, Asia Pacific region is predicted to grow at fastest CAGR during the forecast period owing to the continuous R&D initiatives and growing financing from both public and private institutions. For instance, in October 2022, In order to promote brain cancer research, the Australian government donated more than USD 5.4 million. Medical Research Future Fund (MRFF) is the source of funding.
Rising approval of novel therapeutics for adult malignant gliomas is predicted to boost the market growth during the forecast period. Malignant glioma encompasses a diverse group of tumors affecting the brain and spinal cord, originating from glial cells that support nerve cells in the brain. Tumors can develop from three types of glial cells, known as gliomas. Classification of gliomas is based on the tumor's genetic characteristics and the specific glial cell involved, aiding in predicting the tumor's behavior over time. Symptoms of gliomas include headaches, nausea or vomiting, confusion, decreased brain function, memory loss, seizures, vision problems, among others. With an increasing number of patients, market leaders are actively engaged in the development of innovative therapeutics. For instance, in April 2022, CNS Pharmaceuticals, Inc., has obtained approval from the National Agency for the Safety of Medicine and Health Products (ANSM) Competent Authority and the People Protection Ethics Committee (EC) SUD-EST III (CPP Sud-Est III) in France for the Company's potentially pivotal study of Berubicin in treating recurrent glioblastoma multiforme (GBM).
By type, glioblastoma multiforme (GBM) was the highest revenue-grossing segment in the global adult malignant glioma therapeutics market in 2023 owing to the increased approvals of novel treatments by industry participants and a rise in the number of clinical trial developments. For instance, in December 2022, Moleculin Biotech, Inc., reported that the U.S. Food and Drug Administration ("FDA") has awarded Fast Track designation to WP1122 for addressing Glioblastoma Multiforme ("GBM"). Additionally, anaplastic astrocytoma is predicted to grow at the fastest CAGR during the forecast period owing to the increasing number of surgeries is being performed to treat anaplastic astrocytoma with chemotherapy and radiation therapy and growing launch of novel therapies.
By therapy, targeted drug therapy was the highest revenue-grossing segment in the global adult malignant glioma therapeutics market in 2023 owing to the insufficient outcome of treatments such as surgery, radiation, and chemotherapy, the growing number of researched on the unregulated molecular pathways of gliomas, and the increasing emphasis on the development of new treatments. For instance, in November 2023, Novocure has disclosed that at the 2023 Society for Neuro-Oncology (SNO) Annual Meeting in Vancouver, Canada, there will be presentations on Tumor Treating Fields (TTFields) therapy, encompassing fresh data from the phase 2 2-THE-TOP trial and real-world evidence from patients diagnosed with glioblastoma (GBM) and other central nervous system tumors (CNS). Additionally, radiation therapy is predicted to grow at the fastest CAGR during the forecast period owing to the Increasing the use of external beam radiation after surgery, which is advised as the usual course of treatment for individuals with malignant gliomas.
By end-user, hospitals was the highest revenue-grossing segment in the global adult malignant glioma therapeutics market in 2023 owing to the growing number of patients suffering from brain cancer and increasing regulatory approvals of innovative therapeutic options. For instance, in August 2023, according to a statement from Lisata Therapeutics, Inc., the FDA has designated LSTA1 (CEND-1) as an orphan medication for use as a possible treatment option in patients with malignant glioma. Additionally, cancer and radiation therapy centers is predicted to grow at the fastest CAGR during the forecast period owing to the rising prevalence of cancer, increasing number of clinical trial procedures, and surge in development of novel therapies.
North America region is anticipated for the highest revenue share during the forecast period owing to the increasing incidence of adult malignant glioma, increased emphasis on the development of novel treatments, and an increase in the number of clinical trial methods. For instance, in March 2022, A Phase 0/Ib clinical study of AstraZeneca's AZD1390 has been initiated in patients with recurrent grade IV gliomas at the Barrow Neurological Institute in the US by the Ivy Brain Tumor Center. Additionally, Asia Pacific region is predicted to grow at fastest CAGR during the forecast period owing to the continuous R&D initiatives and growing financing from both public and private institutions. For instance, in October 2022, In order to promote brain cancer research, the Australian government donated more than USD 5.4 million. Medical Research Future Fund (MRFF) is the source of funding.
Report Scope:
- Base Year: 2023
- Forecast Period: 2024-2034
Study Coverage
- Market Forecast by Type, Material, Product, and End-user
- Market Forecast for 5 Regions and 17+ Countries
- North America (U.S. and Canada)
- Europe (Germany, France, UK, Spain, Italy, Russia, Rest of Europe)
- Asia Pacific (China, Japan, India, Australia, South Korea, Rest of APAC)
- Latin America (Brazil, Mexico, Argentina, Rest of LATAM)
- MEA (South Africa, GCC, Rest of MEA)
- Exhaustive Company Profiles of Top 10+ Major Market Players
- 20% Free Customization Available to Meet Your Exact Requirement.
Segmentation: Adult Malignant Glioma Therapeutics Market Report 2023 - 2034
Adult Malignant Glioma Therapeutics Market Analysis & Forecast by Type 2023 - 2034 (Revenue USD Bn)
- Anaplastic Astrocytoma
- Glioblastoma Multiforme
- Anaplastic Oligoastrocytoma
- Anaplastic Oligodendroglioma
- Others
Adult Malignant Glioma Therapeutics Market Analysis & Forecast by Therapy 2023 - 2034 (Revenue USD Bn)
- Radiation Therapy
- Chemotherapy
- Carmustine
- Bevacizumab
- Temozolomide
- Others
- Targeted Drug Therapy
- Epidermal Growth Factor Receptor (EGFR) Inhibitors
- Other Monoclonal Antibodies
Adult Malignant Glioma Therapeutics Market Analysis & Forecast by End-user 2023 - 2034 (Revenue USD Bn)
- Hospitals
- Cancer And Radiation Therapy Centers
- Specialty Clinics
- Others
Adult Malignant Glioma Therapeutics Market Analysis & Forecast by Region 2023 - 2034 (Revenue USD Bn)
- North America
- U.S.
- Canada
- Europe
- Germany
- France
- UK
- Spain
- Italy
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of APAC
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of LATAM
- Middle East & Africa
- South Africa
- GCC
- Rest of MEA
Table of Contents
1. Research Methodology
2. Introduction
4. Market Environment Analysis
5. Market Dynamics
7. Adult Malignant Glioma Therapeutics Market: Type Estimates & Trend Analysis
8. Adult Malignant Glioma Therapeutics Market: Therapy Estimates & Trend Analysis
9. Adult Malignant Glioma Therapeutics Market: End-user Estimates & Trend Analysis
10. Regional Market Analysis
11. North America Adult Malignant Glioma Therapeutics Market
12. Europe Adult Malignant Glioma Therapeutics Market
13. Asia Pacific Adult Malignant Glioma Therapeutics Market
14. Latin America Adult Malignant Glioma Therapeutics Market
15. MEA Adult Malignant Glioma Therapeutics Market
16. Competitor Analysis
17. Company Profiles
Companies Mentioned
- Amgen Inc.
- Bristol-Myers Squibb Company
- AbbVie Inc.
- F. Hoffmann-La Roche Ltd
- Merck & Co. Inc.
- Sun Pharmaceuticals Ltd
- Arbor Pharmaceuticals
- Pfizer Inc.
- Bio Rad Laboratories
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 200 |
| Published | March 2024 |
| Forecast Period | 2023 - 2034 |
| Estimated Market Value ( USD | $ 2.28 Billion |
| Forecasted Market Value ( USD | $ 6.09 Billion |
| Compound Annual Growth Rate | 9.3% |
| Regions Covered | Global |
| No. of Companies Mentioned | 9 |
